What is the appropriate treatment regimen for Helicobacter pylori gastritis?

Treatment of Helicobacter pylori Gastritis

For first-line empiric treatment of H. pylori gastritis, bismuth quadruple therapy (PPI + bismuth + metronidazole + tetracycline) for 14 days is the preferred regimen when antibiotic susceptibility is unknown, achieving eradication rates of approximately 88-89%. 1, 2, 3

First-Line Treatment Selection

The choice of initial therapy depends critically on local clarithromycin resistance patterns and bismuth availability:

In Areas of High Clarithromycin Resistance (>15-20%)

• Bismuth quadruple therapy (PBMT) for 14 days is the first-line recommendation, consisting of:

  • PPI twice daily
  • Bismuth subsalicylate 4 times daily
  • Metronidazole 400-500 mg 3-4 times daily
  • Tetracycline 500 mg 4 times daily 1, 4

• If bismuth is unavailable, concomitant non-bismuth quadruple therapy (PAMC) for 14 days is recommended:

  • PPI twice daily
  • Amoxicillin 1000 mg twice daily
  • Metronidazole 500 mg twice daily
  • Clarithromycin 500 mg twice daily 1, 4

• Sequential therapy is a less ideal alternative if quadruple therapies are not feasible 4

In Areas of Low Clarithromycin Resistance (<15%)

• Clarithromycin-containing triple therapy for 14 days (PPI + amoxicillin + clarithromycin) may be used, though bismuth quadruple therapy remains an excellent alternative 4

• Standard triple therapy should be abandoned when clarithromycin resistance exceeds 15-20%, as efficacy drops to approximately 70% or less 4

Recent U.S. Data

• A 2026 study from Kaiser Permanente Northern California demonstrated that both PACM-14 (concomitant therapy) and PBMT-14 (bismuth quadruple) achieved the highest eradication rates at 89.8% and 88.3% respectively, without substantial decline over time from 2000-2022 3

Critical Treatment Principles

Duration and Dosing

• All first-line regimens should be given for 14 days, as this duration improves eradication rates by approximately 5% compared to shorter courses 1, 4

• High-dose PPI (twice daily) is essential, as it increases cure rates by 6-10% compared to standard dosing 4

• Use potent second-generation PPIs (esomeprazole 40 mg twice daily) when possible for maximum acid suppression 4

Antibiotic History Matters

• Prior macrolide exposure significantly reduces clarithromycin-containing regimen success (adjusted OR 0.68) 3

• Prior metronidazole use reduces metronidazole-containing regimen success (adjusted OR 0.61) 3

• Review antibiotic history before selecting therapy, though this alone may not fully predict outcomes 5

Second-Line (Salvage) Treatment

After first-line treatment failure, eradication rates drop substantially across all regimens:

If Bismuth Quadruple Therapy NOT Previously Used

• Optimized bismuth quadruple therapy (PBMT) for 14 days achieves the highest salvage eradication rate at approximately 69% 1, 2, 3

If Bismuth Quadruple Therapy Previously Used

• Rifabutin triple therapy for 14 days (PPI + amoxicillin + rifabutin 150 mg twice daily or 300 mg once daily) is a suitable empiric alternative 1, 2

• Levofloxacin-containing triple therapy (PPI + amoxicillin + levofloxacin 500 mg daily) for 14 days is an option, but only if levofloxacin susceptibility is confirmed or local resistance is low 1, 4, 6

Novel Second-Line Options

• Tetracycline-levofloxacin quadruple therapy (PPI + bismuth + tetracycline + levofloxacin) achieved 98% eradication in trials, superior to levofloxacin-amoxicillin triple therapy at 69% 6

• High-dose PPI-amoxicillin dual therapy can achieve 89% eradication rates for second-line treatment 1, 6

Third-Line Treatment

• Antibiotic susceptibility testing should guide therapy whenever possible after two treatment failures 4

• If susceptibility testing unavailable, use antibiotics not previously prescribed: amoxicillin, tetracycline, bismuth, or furazolidone 7

• Never repeat a previously failed regimen, as this reduces eradication rates by approximately 50% (adjusted OR 0.46-0.51) 3

Special Populations

Penicillin Allergy

• In low clarithromycin resistance areas: PPI + clarithromycin + metronidazole for 14 days 4

• In high clarithromycin resistance areas: Bismuth quadruple therapy (which contains tetracycline, not penicillin) 4

• For salvage: Levofloxacin + clarithromycin + PPI in areas of low fluoroquinolone resistance 4

Confirmation of Eradication

• Universal test-of-cure is recommended for all patients at least 4 weeks after completing therapy 4, 2

• Urea breath test or validated monoclonal stool antigen test are the preferred non-invasive methods 4

• Serology has no role in confirming eradication 4

Common Pitfalls to Avoid

• Do not use 7-10 day regimens; 14 days is superior 1, 4

• Do not use standard-dose PPIs once daily; high-dose twice daily is essential 4

• Do not use ciprofloxacin instead of levofloxacin or moxifloxacin for fluoroquinolone-based therapy 4

• Do not use doxycycline instead of tetracycline HCl 4

• Do not prescribe levofloxacin to patients with chronic respiratory conditions who may have prior fluoroquinolone exposure 4

• Do not skip test-of-cure, as eradication testing rates remain suboptimal at only 50-64% despite guideline recommendations 5